DxDiscovery, Inc.
DxDiscovery is a biotechnology research and development firm focused on developing high-quality, high-affinity antibodies to microbial antigens. These antibodies are incorporated into rapid, point-of-care diagnostics or developed as prophylactics/therapeutics for infectious diseases. The company's mission is to enhance global health through early, rapid, and inexpensive diagnostic tests, aiming to be a leader in biomarker discovery and immunoassay development. DxDiscovery collaborates with academic and clinical partners across the United States and has a history of successful partnerships and funding from NIH and the Department of Defense. Its work includes developing diagnostics for diseases such as pertussis, coccidioidomycosis, mucormycosis, Lyme disease, and citrus greening, utilizing immunoassay platforms like lateral flow immunoassays and ELISA. The company emphasizes early diagnosis to improve patient outcomes and reduce healthcare costs.
Industries
Nr. of Employees
small (1-50)
DxDiscovery, Inc.
Applied Research Facility MS 0525, 1664 N. Virginia St., Reno, NV 89557
Patents
Products
Rapid lateral flow immunoassay for pertussis (developmental)
A point-of-care lateral flow immunoassay designed to detect Bordetella pertussis antigens from nasopharyngeal specimens with results in under 20 minutes.
Coccidioidomycosis antigen-detection ELISA and LFIA (developmental)
Antigen-capture ELISA kit and complementary lateral flow immunoassay for detection of Coccidioides cell-wall polysaccharides from urine or serum to enable rapid diagnosis.
Mucormycosis lateral flow immunoassay (developmental)
A rapid lateral flow immunoassay intended for early detection of mucormycosis using non- or minimally-invasive specimens (urine, serum, plasma) to reduce need for invasive biopsies.
Lyme disease antigen and field-deployable tick assay (developmental)
Development of assays to detect Borrelia burgdorferi antigens for earlier patient diagnosis and field-deployable assays for surveillance of infected ticks.
Citrus greening (Huanglongbing) LFIA and quantitative ELISA (developmental)
Field-friendly lateral flow immunoassay and complementary quantitative ELISA to detect Candidatus Liberibacter asiaticus in trees and insect vectors to support on-site orchard decision-making.
Tinea capitis and onychomycosis rapid diagnostic (developmental)
Rapid diagnostic for dermatophyte infections intended for early identification in clinical settings.
Rapid lateral flow immunoassay for pertussis (developmental)
A point-of-care lateral flow immunoassay designed to detect Bordetella pertussis antigens from nasopharyngeal specimens with results in under 20 minutes.
Coccidioidomycosis antigen-detection ELISA and LFIA (developmental)
Antigen-capture ELISA kit and complementary lateral flow immunoassay for detection of Coccidioides cell-wall polysaccharides from urine or serum to enable rapid diagnosis.
Mucormycosis lateral flow immunoassay (developmental)
A rapid lateral flow immunoassay intended for early detection of mucormycosis using non- or minimally-invasive specimens (urine, serum, plasma) to reduce need for invasive biopsies.
Lyme disease antigen and field-deployable tick assay (developmental)
Development of assays to detect Borrelia burgdorferi antigens for earlier patient diagnosis and field-deployable assays for surveillance of infected ticks.
Citrus greening (Huanglongbing) LFIA and quantitative ELISA (developmental)
Field-friendly lateral flow immunoassay and complementary quantitative ELISA to detect Candidatus Liberibacter asiaticus in trees and insect vectors to support on-site orchard decision-making.
Tinea capitis and onychomycosis rapid diagnostic (developmental)
Rapid diagnostic for dermatophyte infections intended for early identification in clinical settings.
Services
Development of monoclonal antibodies, associated cell lines, and reagent characterization for diagnostic or research use; licensing options available.
Design and build antigen-capture ELISA kits and lateral flow immunoassay prototypes optimized for laboratory or point-of-care use, including prototype manufacturing and iterative optimization.
Proteomic analysis and microbial biomarker identification in complex samples to inform target selection for diagnostics.
Performance testing of diagnostic prototypes using archived clinical specimens and animal model samples to generate preclinical/clinical evaluation data.
Screening and integration of synthetic small molecules that bind target proteins to create antibody-free rapid detection chemistries.
Development of field-deployable nucleic acid amplification tests using isothermal technologies for decentralized pathogen detection.
Development of monoclonal antibodies, associated cell lines, and reagent characterization for diagnostic or research use; licensing options available.
Design and build antigen-capture ELISA kits and lateral flow immunoassay prototypes optimized for laboratory or point-of-care use, including prototype manufacturing and iterative optimization.
Proteomic analysis and microbial biomarker identification in complex samples to inform target selection for diagnostics.
Performance testing of diagnostic prototypes using archived clinical specimens and animal model samples to generate preclinical/clinical evaluation data.
Screening and integration of synthetic small molecules that bind target proteins to create antibody-free rapid detection chemistries.
Development of field-deployable nucleic acid amplification tests using isothermal technologies for decentralized pathogen detection.
Expertise Areas
- Biomarker discovery for infectious disease
- Monoclonal antibody generation
- Immunoassay development (ELISA and lateral flow)
- Point-of-care diagnostic development
Key Technologies
- Monoclonal antibody development
- Lateral flow immunoassay (LFIA)
- Antigen-capture ELISA
- Isothermal nucleic acid amplification (NAAT)
News & Updates
Prompt diagnosis of early pertussis (Whooping cough) is critical for minimizing the extent and economic burden of pertussis outbreaks. The company received a Phase IIB SBIR grant to develop a rapid, point-of-care immunoassay for early detection of pertussis.
Coccidioidomycosis is a serious fungal pneumonia prevalent in the southwest US and northern Mexico. DxDiscovery received a Phase II SBIR contract to develop a rapid immunoassay for its detection, aiming for use at or near the point of care.
DxDiscovery received defense funding to develop rapid assays that replace antibodies with small molecule moieties, enabling timely development of diagnostics during outbreaks.
DxDiscovery was announced as one of seven finalists in the Sontag competition.
DxDiscovery moved to the Applied Research Facility, marking a significant step in its development.
DxDiscovery was featured on MyNews 4, highlighting its role as a Nevada biotechnology company.
Prompt diagnosis of early pertussis (Whooping cough) is critical for minimizing the extent and economic burden of pertussis outbreaks. The company received a Phase IIB SBIR grant to develop a rapid, point-of-care immunoassay for early detection of pertussis.
Coccidioidomycosis is a serious fungal pneumonia prevalent in the southwest US and northern Mexico. DxDiscovery received a Phase II SBIR contract to develop a rapid immunoassay for its detection, aiming for use at or near the point of care.
DxDiscovery received defense funding to develop rapid assays that replace antibodies with small molecule moieties, enabling timely development of diagnostics during outbreaks.
DxDiscovery was announced as one of seven finalists in the Sontag competition.
DxDiscovery moved to the Applied Research Facility, marking a significant step in its development.
DxDiscovery was featured on MyNews 4, highlighting its role as a Nevada biotechnology company.